The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
-
University of Iowa Hospital, Iowa City, Iowa, United States, 52242
University of Kentucky, Lexington, Kentucky, United States, 40506
Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905
Rutgers University, New Brunswick, New Jersey, United States, 08901
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106
University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Janssen Research & Development, LLC,
Janssen Research & Development, LLC Clinical Trial, STUDY_DIRECTOR, Janssen Research & Development, LLC
2027-05-31